FRM
RCKT icon

Fox Run Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Fox Run Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,047
Closed -$120K – 1160
2025
Q1 		$120K Buy
+18,047
New +$178K 0.02% 854
2024
Q1 		– Sell
-7,353
Closed -$220K – 1012
2023
Q4 		$220K Buy
+7,353
New +$162K 0.06% 608
2022
Q2 		– Sell
-16,594
Closed -$263K – 712
2022
Q1 		$263K Buy
+16,594
New +$287K 0.15% 322

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Fox Run Management's RCKT Position: Q2 2025 in Review

Fox Run Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 18,047 shares — an estimated $120K sold.

Fox Run Management first reported a position in RCKT in Q1 2022 and held it in 3 quarters. The position peaked at $263K in Q1 2022. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Fox Run Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 18,047 Rocket Pharmaceuticals shares in Q2 2025, an estimated $120K.
  • Fox Run Management first reported a position in Rocket Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Fox Run Management's Rocket Pharmaceuticals position peaked at $263K in Q1 2022.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.